RBC Capital Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $273

Benzinga · 3d ago
RBC Capital analyst Leonid Timashev maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and lowers the price target from $295 to $273.